A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. - Wikidata - wikimedia - TriplyDB

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

http://www.wikidata.org/entity/Q37316153

about

Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Alzheimer's therapeutics: translation of preclinical science to clinical drug development γ-Secretase inhibitors and modulators.Testing the right target and right drug at the right stage New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Clinical trial methodologies for disease-modifying therapeutic approaches Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease Notch γ-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease Decreased clearance of CNS beta-amyloid in Alzheimer's disease Amyloid β-Protein Assembly: The Effect of Molecular Tweezers CLR01 and CLR03 Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data.Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.Multimodal techniques for diagnosis and prognosis of Alzheimer's disease CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study.Cerebrospinal fluid biomarkers of Alzheimer's disease.Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.Targeting Abeta and tau in Alzheimer's disease, an early interim report Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects.A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease The secretases: enzymes with therapeutic potential in Alzheimer disease.Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound Alzheimer's disease and disseminated mycoses.Beyond the signaling effect role of amyloid-ß42 on the processing of APP, and its clinical implications Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system.Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Alzheimer's disease: which type of amyloid-preventing drug agents to employ?A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice.Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.Biomarkers of the dementia.Computational drug repositioning through heterogeneous network clustering.

P2860

Q26784569-03492610-71EF-469B-AB0F-AB8B8D95F7D4 Q26829267-DFD700C0-4D7C-45E2-991C-5143188FF78B Q26830462-8F046ED1-F090-41F5-A0C6-598BFD6CB986 Q26864854-9E8DD04B-0E4A-4261-9F8D-45B4E1E85B68 Q26866006-00DA3969-EFCC-4DF3-8697-B98AAD2727A0 Q27001770-187703A6-92CB-47C3-B03F-4C7DA7F27A34 Q27674362-EFC0C359-C4F1-4ABE-8B84-B6E6A5F9DD27 Q28537641-A1C5E6BE-B1F2-4824-9A0D-C51F0AB29265 Q28743561-8B3A3A9C-F1A4-4AEE-8811-CB86519C5BA4 Q29616534-6BAEDFA9-30CE-4CCC-A685-D77A148BA8D9 Q29999197-8885A027-4BDD-48C4-B79E-1BFD698FDDBA Q30584453-0E95F88D-A76E-4217-B24E-62471E473A1B Q30871982-281FCE83-144A-48B2-8909-25C72C4BB685 Q33607535-21F6F86C-1E8D-486E-9D30-A856CCC0A767 Q33735544-34CE76C2-951C-4034-A26B-447D35725D6D Q33746272-E0DA4553-DFF7-448E-B93D-841B8005325E Q33757828-4304656F-D9A9-4CC1-B72A-A3C2152C443E Q33809324-343E19F6-73CF-4225-9743-53C83849E78A Q33829008-FD8F8E0E-8724-4A01-A051-C204B8F10142 Q33862796-DA4DEFE5-6040-4BA2-B38B-E8C8E8AE513D Q33877903-F28D70BA-1BEE-496D-A445-CEE78E8C2D46 Q33887222-B0ACCB04-FBFE-4129-9944-1C05B89EE094 Q33967781-4445E62A-34FC-4D84-901E-079E0AC65950 Q34014237-6A081258-6F76-4F66-83E0-07F91709F238 Q34036136-14539ACD-5A04-4426-BE5D-4618B98BFE26 Q34039644-26DFEC75-0E1B-4777-A54F-55E863B3C111 Q34069264-E421CD53-7B46-484C-AB0C-5BF919BBC945 Q34215733-64F6B892-8A81-4C84-92A0-9A4E41F3C954 Q34219001-3EB1592F-20A7-4F40-A6F0-468D4A57CDAD Q34222721-C105C660-477F-48DD-A3E7-1B33E99C62B6 Q34330351-E1DB0975-EC6F-4775-961A-4EB9EF2A0D80 Q34376103-A1C7807F-606B-4F92-8AAD-776D437E820C Q34380018-8C94FFC6-E06D-4443-BCE5-FD25C09D090B Q34407220-82B6B3B4-6710-4561-9643-4AF9F60C6748 Q34630346-5A2F33D2-9DE3-444F-B367-1152F9D2B6BB Q34723920-6436A083-45A1-4FAD-965A-84E9323F3FC5 Q34735454-AB03674C-1FD4-485F-BFA3-061E33DA0E06 Q35029086-CBEF6A4A-8396-4424-8324-9A7C88A9274B Q35030049-9D66ACBF-AA3C-4D54-B7D7-F702CCD79784 Q35101970-0DF879A2-6A9F-424F-AAC6-72F1FC503CCC

P2860

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

http://www.wikidata.org/entity/Q37316153

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A gamma-secretase inhibitor de ...... in the central nervous system.

@en

A gamma-secretase inhibitor de ...... in the central nervous system.

@nl

type

label

A gamma-secretase inhibitor de ...... in the central nervous system.

@en

A gamma-secretase inhibitor de ...... in the central nervous system.

@nl

prefLabel

A gamma-secretase inhibitor de ...... in the central nervous system.

@en

A gamma-secretase inhibitor de ...... in the central nervous system.

@nl

P1433

Q37316153-2E90BDA6-45DE-431F-B794-8F2B6B42435C

P1476

Q37316153-CAB6F8A4-E309-4FC0-BB73-58F79A89661C

P2093

Q37316153-02C165D5-006A-42F0-B4C6-25465E6BE595

Q37316153-2718B244-893A-4E3D-97CA-7B163C53D60A

Q37316153-4B329032-5BB2-4222-99E5-3F8D0A16A84B

Q37316153-4F6F8FE3-7A70-4039-9A6E-698CDC5BF238

Q37316153-6C658AD0-15EF-41A8-8B18-04AA52BB0B79

Q37316153-736A61AC-BD53-46EB-B17D-4C46FB2C8E13

Q37316153-7D75E7FE-FDB0-496C-BDE0-D862537FBB8E

Q37316153-8E4F002B-9D79-4AB8-BE7E-8F9E2EFE36F9

Q37316153-C086D757-E222-4ED6-B792-B00FC3CE8A7E

P2860

Q37316153-01C40C35-1B7B-42F6-890B-10A5F32F32AC

Q37316153-0DAECA47-6EF6-4834-9378-38CFC1E943DB

Q37316153-17B731D6-B1AF-43E4-879D-C2FFB7145CE4

Q37316153-2F3B3605-4029-4434-A2CC-BDAB9E8FBD33

Q37316153-3A70D698-45E8-437A-9FFB-08D16B22FA96

Q37316153-4F74A766-301A-4F33-B49B-E329E22D29CD

Q37316153-58508173-F517-44EC-9591-FDBA011E253E

Q37316153-624BFCBD-BE79-4094-9D51-415F5142D94C

Q37316153-664062FB-F0C9-4E19-89D3-5BEFDE9E45C0

Q37316153-7D291ABF-732E-4601-B16D-8EB429A34D43

P304

Q37316153-731CAD83-8693-4DE3-8ECD-C2F6305ACD16

P31

Q37316153-66F4D8E6-271E-4DAC-9DE2-881FE9B9230B

P356

Q37316153-51005117-906E-4FBC-B652-65A5680DD171

P433

Q37316153-F3AD111C-3873-43AC-872E-C94C5BEB689A

P478

Q37316153-5DA9B1C5-828E-4A0C-A699-8829BD3AF62D

P50

Q37316153-78A6EEF5-28FF-4756-B27C-4D88FB57AEEA

Q37316153-BE48D3BA-CBAA-4E2C-8617-887804028459

Q37316153-F8A16357-D6F3-4496-B5A3-BDF0915E9B9E

P577

Q37316153-62C85D59-8475-4E18-BA21-8988F6E01ECF

P5875

Q37316153-41DC98BA-9DE6-4964-8D7D-7597C68B3CED

P698

Q37316153-2D4B1FF4-00D2-4A05-9A58-93B000E31EDC

P932

Q37316153-C2C03183-FA34-4A4D-865E-9DC70AEC2049

P356

P1433

Annals of Neurology

P1476

A gamma-secretase inhibitor de ...... in the central nervous system.

@en

P2093

Eric R Siemers

http://www.w3.org/2001/XMLSchema#string

Guolin Wen

http://www.w3.org/2001/XMLSchema#string

Karen R Browning

http://www.w3.org/2001/XMLSchema#string

Kwasi G Mawuenyega

http://www.w3.org/2001/XMLSchema#string

Patrick C May

http://www.w3.org/2001/XMLSchema#string

Ronald B Demattos

http://www.w3.org/2001/XMLSchema#string

Steven M Paul

http://www.w3.org/2001/XMLSchema#string

Stuart W Friedrich

http://www.w3.org/2001/XMLSchema#string

Wendy C Sigurdson

http://www.w3.org/2001/XMLSchema#string

P2860

Alzheimer Disease in the US Population

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

The discovery and development of HMG-CoA reductase inhibitors

Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities

Alzheimer's disease

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

Therapeutic effects of ML-236B in primary hypercholesterolemia.

Deciphering the molecular basis of memory failure in Alzheimer's disease.

P304

48-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.21623

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Randall J. Bateman

Kevin Yarasheski

David M. Holtzman

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24272345

http://www.w3.org/2001/XMLSchema#string

P698

19360898

http://www.w3.org/2001/XMLSchema#string

P932

2730994

http://www.w3.org/2001/XMLSchema#string